Analysts expect MacroGenics, Inc. (NASDAQ:MGNX) to post earnings of ($1.03) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for MacroGenics’ earnings, with the highest EPS estimate coming in at ($0.77) and the lowest estimate coming in at ($1.21). MacroGenics reported earnings per share of ($0.97) in the same quarter last year, which indicates a negative year-over-year growth rate of 6.2%. The business is expected to report its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that MacroGenics will report full-year earnings of ($4.26) per share for the current fiscal year, with EPS estimates ranging from ($4.69) to ($3.77). For the next fiscal year, analysts expect that the business will report earnings of ($3.94) per share, with EPS estimates ranging from ($4.76) to ($3.18). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow MacroGenics.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.09). The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The company’s revenue was down 97.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.12 earnings per share.

Several research analysts have recently issued reports on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $34.00 target price on shares of MacroGenics in a research note on Tuesday, September 12th. SunTrust Banks, Inc. restated a “buy” rating and set a $26.00 target price on shares of MacroGenics in a report on Friday, September 1st. Zacks Investment Research downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. ValuEngine downgraded shares of MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. Finally, BidaskClub upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $30.30.

ILLEGAL ACTIVITY WARNING: “MacroGenics, Inc. (MGNX) Expected to Post Earnings of -$1.03 Per Share” was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/24/macrogenics-inc-mgnx-expected-to-post-earnings-of-1-03-per-share-2.html.

Shares of MacroGenics (NASDAQ:MGNX) traded down 2.67% during mid-day trading on Tuesday, hitting $16.39. 87,924 shares of the stock were exchanged. The company’s 50-day moving average is $17.69 and its 200-day moving average is $18.14. MacroGenics has a 1-year low of $14.36 and a 1-year high of $31.85. The firm’s market cap is $603.12 million.

Hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new position in MacroGenics in the second quarter valued at about $133,000. Legal & General Group Plc raised its stake in MacroGenics by 4.3% in the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 328 shares in the last quarter. SG Americas Securities LLC raised its stake in MacroGenics by 92.2% in the second quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 5,187 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new position in MacroGenics in the second quarter valued at about $203,000. Finally, Virtu KCG Holdings LLC acquired a new position in MacroGenics in the second quarter valued at about $232,000. 84.63% of the stock is owned by institutional investors and hedge funds.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Get a free copy of the Zacks research report on MacroGenics (MGNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.